(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix - 2Extreme Manual for Purchasing Your Next Truck
- 3The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- 4'All Her Fault' ending explained: The shocking conclusion to the psychological thriller inspired by true events
- 5An Extended time of Self-Reflection: Self-awareness through Journaling
- Audits of Espresso Types: Which Mix Is for You?
- Famous Versatile Brands: Your Decision
- Which Film Has the Incomparable Melodic Score?
- Vote In favor of Your Number one Cell phones
- Manual for Superstars Known for Their Altruistic Endeavors
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- 5 Worldwide Road Food sources You Should Attempt
- Most loved Occasion Dish: What Makes Your Bubbly Table?
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
